Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ALPHA-FETOPROTEIN TEST CLINICAL INVESTIGATOR EDUCATION BY MANUFACTURERS

This article was originally published in The Gray Sheet

Executive Summary

ALPHA-FETOPROTEIN TEST CLINICAL INVESTIGATOR EDUCATION BY MANUFACTURERS should be conducted to ensure proper interpretation of results, FDA says in a July 15 premarket guidance document on AFP tests for open neural tube defects. "Each manufacturer must ...educate each of the investigators [involved in the sponsor's clinical study] to the dangers in the use of incorrect reference data," the document says, adding that the use of incorrect reference data is "a common cause of incorrect interpretation of MSAFP (maternal serum alpha-fetoprotein) testing measurements by physicians and laboratorians."

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel